We apologize your item could not be found. Not all items are listed on our website. Please contact your account manager for details regarding your searched item.
Material number (eg: xxxxxxxxxxx) no space or hyphen needed.
No Results Found
Pharmaceutical drug development and commercial manufacturing is complex and risky. Packaging and drug delivery add challenges. With West by your side, you can find solutions to industry challenges such as:
As drug manufacturers aim for higher safety standards and enhanced patient care, controlling the drug product at the point-of-use in a hospital or clinical environment remains a significant challenge. The method of vial access often varies, increasing the risk of adverse patient outcomes, such as stopper cores or fragments entering the drug product. If injected, these fragments can lead to cardiovascular events and other complications. Several factors contribute to stopper coring and fragmentation in the field, primarily influenced by the technique of the practitioner and the properties of the elastomeric closure.
Contamination control has come to dominate conversations around implementation of the revised European Union’s Good Manufacturing Practice Annex 1 (EU GMP Annex 1).
Development in gene therapies is continually increasing – presently over 1,400 companies are involved, with over 2,200 clinical trials underway. It is essential to find an appropriate containment system to protect the time and monetary investments required to create these treatments.
As drug manufacturers aim for higher safety standards and enhanced patient care, controlling the drug product at the point-of-use in a hospital or clinical environment remains a significant challenge. The method of vial access often varies, increasing the risk of adverse patient outcomes, such as stopper cores or fragments entering the drug product. If injected, these fragments can lead to cardiovascular events and other complications. Several factors contribute to stopper coring and fragmentation in the field, primarily influenced by the technique of the practitioner and the properties of the elastomeric closure.
Contamination control has come to dominate conversations around implementation of the revised European Union’s Good Manufacturing Practice Annex 1 (EU GMP Annex 1).
Development in gene therapies is continually increasing – presently over 1,400 companies are involved, with over 2,200 clinical trials underway. It is essential to find an appropriate containment system to protect the time and monetary investments required to create these treatments.
English
Chinese
